ClinicalTrials.gg
CompletedNCT00801294Updated Dec 29, 2017

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

A Phase 2 interventional study of BIBF 1120 and BIBW 2992 in Colorectal Neoplasms, sponsored by Boehringer Ingelheim. Completed at 24 sites in France. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2017-12-29.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Jul 2006, registered Dec 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim — 1 open to participants now, 2 under way, none of them phase 3. Colorectal Neoplasms · Boehringer Ingelheim.

Enrollment
8th of 14
46 · median 57
Started
2006
the only one that year
Phase 2
5 of 14
none open now
Registered
1st of 14
by date

Among the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, this one is the 8th largest by enrollment, is the only one that started in 2006, is one of 5 in phase 2, and was the 1st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The primary objective of this trial is to explore the overall objective best response rate and the rate of non-progression at 16 weeks of sequential, alternating weekly administration of BIBF 1120 and BIBW 2992 in patients with metastatic CRC based on the RECIST criteria.

03

Conditions studied

  • Colorectal Neoplasms
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age over 18 years.
  2. Signed .
  3. proven colorectal adenocarcinoma
  4. History or presence of colorectal cancer (stage IV)
  5. Measurable (>1 cm) or evaluable tumour deposit (according to criteria)
  6. Documented progression or unacceptable toxicity on the last therapy
  7. Progression on oxaliplatin-based chemotherapy or unacceptable residual neurotoxicity on oxaliplatin
  8. Progression on irinotecan-based chemotherapy or unacceptable toxicity on irinotecan
  9. If patients have been previously exposed to Cetuximab or other EGFR inhibitor, they must have shown progression or unacceptable toxicity
  10. If patients have been previously exposed to Bevacizumab or other VEGF inhibitor, they must have shown progression or unacceptable toxicity
  11. of at least 12 weeks.
  12. WHO () performance status \<= 2, \<= 1 if age > 75 years.
  13. Adequate hepatic function
  14. Adequate renal function

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with small molecule EGFR, or VEGFR tyrosine kinase inhibitors
  2. Treatment with standard chemotherapy or cetuximab within the last 14 days
  3. Treatment with bevacizumab within the last 28 days
  4. History of other in the last 5 years, which could affect compliance with the protocol or interpretation of results. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
  5. Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality
  6. Significant cardiovascular diseases
  7. History of haemorrhagic or thrombotic event in the past 12 months. Known inherited predisposition to bleeds or to thrombosis.
  8. Patient with history or clinical or radiological evidence of CNS disease or .
  9. Pregnancy or breast-feeding
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
46 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The RECIST criterion will be used to assess: objective response rate (PR + CR), and disease progression within the first 16 weeks

    Time frame: every 4 weeks

  2. PFS

    Time frame: 16 weeks

Secondary outcomes

  1. Progression-free survival (based on the RECIST criteria)

    Time frame: 66 Weeks

  2. Overall survival

    Time frame: 66 Weeks

  3. The incidence and intensity of Adverse Events with grading of Adverse Events according to the US NCI Common Terminology Criteria for Adverse Events (CTCAE version 3.0)

    Time frame: 66 Weeks

  4. Changes in safety laboratory parameters

    Time frame: 66 Weeks

  5. Effectiveness of dose reduction guidelines in managing adverse events

    Time frame: 66 Weeks

07

Study locations

24 sites
  • 1239.2.3305A clinique Saint Jean
    Lyon, France
  • 1239.2.3305B Cabinet Médical
    Lyon, France
  • 1239.2.3301A Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301B Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301C Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301D Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301E Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301F Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301G Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301H Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301I Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301J Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3301K Hôpital Saint Antoine
    Paris Cedex 12, France
  • 1239.2.3302A Hôpital Tenon
    Paris Cedex 20, France
  • 1239.2.3302B Hôpital Tenon
    Paris Cedex 20, France
  • 1239.2.3304A Hôpital Robert Debré
    Reims Cedex, France
  • 1239.2.3304B Hôpital Robert Debré
    Reims Cedex, France
  • 1239.2.3304C Hôpital Robert Debré
    Reims Cedex, France
  • 1239.2.3303A Institut Gustave Roussy
    Villejuif Cedex, France
  • 1239.2.3303B Institut Gustave Roussy
    Villejuif Cedex, France
  • 1239.2.3303C Institut Gustave Roussy
    Villejuif Cedex, France
  • 1239.2.3303D Institut Gustave Roussy
    Villejuif Cedex, France
  • 1239.2.3303E Institut Gustave Roussy
    Villejuif Cedex, France
  • 1239.2.3303F Institut Gustave Roussy
    Villejuif Cedex, France
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2006 to primary completion in Nov 2007, 16 months.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 16 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2008
First posted
Dec 3, 2008
StartActual
Jul 1, 2006
Primary completionActual
Nov 1, 2007
Last update
Dec 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00801294
Responsible party
Sponsor
First posted
Dec 3, 2008
Start date
Jul 1, 2006
Primary completion
Nov 1, 2007
Last update
Dec 29, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · Afatinib

Start the discussion